Korean Circ J.  2001 Dec;31(12):1274-1280. 10.4070/kcj.2001.31.12.1274.

The Clinical Effects of Tranilast on Restenosis after Percutaneous Transluminal Coronary Angioplasty

• Jeong WK
• Jeong MH
• Kim KH
• Jhu IK
• Lee SR
• Park OY
• Yum JH
• Kim W
• Kim JH
• Rhew JY
• Ahn YK
• Kim YC
• Cho JG
• Park JC
• Kang JC

• KMID: 1938917
• DOI: http://doi.org/10.4070/kcj.2001.31.12.1274

Abstract

BACKGROUND AND OBJECTIVES
Tranilast is an anti-allergic drug that suppresses the release of cytokines, such as platelet-derived growth factor, transforming growth factor-beta and interleukin-1beta. It has recently become known to be effective in the prevention of restenosis following PTCA (percutaneous transluminal coronary angioplasty).
SUBJECTS AND METHODS
One hundred forty two consecutive patients with angina who underwent PTCA between Jan 1999 and Jul 2000 at Chonnam National University Hospital were analyzed prospectively. Thirty patients (Tranilast group:60.8+/-7.7 years, M:F=22:8, 41 lesions) out of 48 who received 300 mg tranilast for 3 months following PTCA and who underwent follow-up CAG (coronary angiogram), were compared with 61 patients (Control group:58.1+/-11.0 years, M:F=52:9, 82 lesions) out of 94, 94 who did not receive tranilast but did undergo follow-up CAG.
RESULTS
The restenosis rate per lesion was significantly lower in the Tranilast group than in the Control group on the 6-month follow-up CAG (Tranilast vs. Control group:19.5% vs. 40.2%, p=0.021). The minimal luminal diameter was significantly larger in the Tranilast group as compared to the Control group (1.99+/-0.76 vs. 1.50+/-0.83 mm p=0.002). One patient of the Tranilast group suffered from liver dysfunction and stopped medication.
CONCLUSION
The oral administration of tranilast is safe and effective in the prevention of restenosis following PTCA in patients with angina.

Keyword

Tranilast; Restenosis; Coronary disease; Angioplasty, transluminal, percutaneous coronary

MeSH Terms

Administration, Oral
Angioplasty, Balloon, Coronary*
Coronary Disease
Cytokines
Follow-Up Studies
Humans
Interleukin-1beta
Jeollanam-do
Liver Diseases
Phenobarbital
Platelet-Derived Growth Factor
Prospective Studies
Cytokines
Interleukin-1beta
Phenobarbital
Platelet-Derived Growth Factor